CALGB 10603 (RATIFY): A randomized phase III study of induction (daunorubicin/cytarabine) and consolidation (high-dose cytarabine) chemotherapy combined with midostaurin or placebo in treatment-naive patients with FLT3 mutated AML.
R. M. Stone
Consultant or Advisory Role - Novartis
H. Dohner
No relevant relationships to disclose
G. Ehninger
Stock Ownership - Novartis
Honoraria - Novartis
M. Villeneuve
No relevant relationships to disclose
T. Teasdale
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
J. D. Virkus
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
L. R. Bressler
No relevant relationships to disclose
M. M. Seiler
No relevant relationships to disclose
G. Marcucci
No relevant relationships to disclose
R. A. Larson
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis